Jabio's ST Status Highlights Valuation Traps in Synthetic Biology

I noticed an interesting detail: hidden within Jiabiyou's ST (Special Treatment) announcement is a signal that asset allocators least want to see—the pricing power of a company's core assets was easily breached by overseas regulation and public opinion.

This STAR Market synthetic biology company, once crowned as the "world's second-largest ARA manufacturer," now faces the "ST Jiabiyou" label. On the evening of July 24, the company disclosed a projected interim loss exceeding 100 million yuan, while announcing that production and operations were still affected by overseas market sentiment and new regulatory requirements, and had not yet recovered. From an asset allocation perspective, this isn't just a simple performance fluctuation, but a concentrated exposure of business model fragility.

Jiabiyou's main business is the production of microbial oils such as Arachidonic Acid (ARA) and Algal DHA, a typical application of synthetic biology in food additives. Its core logic is: replacing traditional chemical synthesis or animal extraction with biological fermentation, which is lower cost and more eco-friendly. Sounds great, but the problem is that customers for these products are concentrated among infant formula companies like Nestlé, Feihe, and Yili. High downstream concentration means upstream raw material suppliers naturally have weak bargaining power.

I did a simple stress test: Assume Jiabiyou's single export market (e.g., Europe) halts orders due to food safety sentiment or new regulations. Does the company have the ability to quickly switch markets? The answer is no. Because global capacity for ARA and DHA is concentrated among a few manufacturers, and although Jiabiyou ranks second, customer certification cycles are long and brand trust costs are high. Once negative sentiment arises, downstream formula companies will immediately switch to backup suppliers—like DSM, a giant in the field. This isn't a technical issue; it's a trust issue.

From a risk-reward ratio perspective, Jiabiyou is facing a variant of the "Davis Double Kill": declining revenue compounded by asset impairments, while the stock price has already fallen nearly 70% over the past year. But this doesn't mean the bottom is in sight, because after being tagged ST, institutional investors' risk control requirements will force position reductions, and liquidity will further dry up.

What makes me more wary is that Jiabiyou's plight is not isolated. The synthetic biology sector was highly sought after in 2021-2022, with capital betting on the vision of "manufacturing everything with microbes." But the reality is that most synthetic biology products lack patent moats, technical barriers are easily replicated, and the final competitive barriers often fall on cost control and customer relationships. And these two points are precisely Jiabiyou's weaknesses.

The company emphasized its "global second place" capacity status in financial reports, but capacity does not equal market position. When overseas regulators require resubmission of safety assessment reports under the guise of "new food ingredients," Jiabiyou's capacity advantage instantly turns into inventory pressure. The projected interim loss of over 100 million yuan largely comes from inventory write-downs—this confirms an investment common sense: perishable biological raw material inventories carry risks far higher than standardized industrial goods.

From a valuation logic perspective, Jiabiyou enjoyed a high valuation premium upon listing on the STAR Market, with PE ratios once exceeding 80x. The market's pricing was based on assumptions of "high growth + scarcity." But now, the projected interim loss means the growth logic has been falsified, and scarcity has been diluted by DSM's global network. For family offices, the valuation anchor for such targets should revert to the level of chemical raw material companies—that is, 10-15x PE, or even lower, given their low asset turnover and high customer dependency.

I noticed an interesting detail: Jiabiyou's "ST tagging" happened exactly against the backdrop of a general pullback in synthetic biology concept stocks. This indicates that the market is repricing the risks of this sector. As asset allocators, we should distinguish between two types of biotech companies: one type possesses platform technology capable of continuously launching new products (like the Ginkgo Bioworks model), and the other is single-product dependent, essentially just an "advanced chemical plant." Jiabiyou clearly belongs to the latter.

Looking at competitive barriers, Jiabiyou's biggest moat is actually "first-mover advantage" and "customer certification cycles," but these barriers crumble before regulation and public opinion. Once overseas customers require recertification, approval processes lasting several months can cause cash flow breaks. What family offices hate most is this kind of "unpredictable tail risk."

For investors holding Jiabiyou, the most rational choice right now is to stop losses. Because after the ST tag, the core issue the company needs to solve isn't expanding capacity or reducing costs, but rebuilding trust with overseas customers—this takes time, and the outcome is highly uncertain. For those watching from the sidelines, it might be better to wait until the company completes overseas regulatory reviews and resumes exports, then observe the true strength of its revenue recovery. At that point, if the company can prove its customer stickiness, perhaps its risk-reward ratio can be reassessed.

One-sentence summary: Jiabiyou's plight reminds us that in the biotech field, raw material suppliers without patent and brand barriers are essentially cyclical chemical companies and do not deserve growth-stock valuations.

Original link: https://www.tmtpost.com/8081276.html